25 January 2024 - The outcomes from the December 2023 PBAC intracycle meeting are now available.

The PBAC recommended the listing of:

• Patisiran sodium (Onpattro) - new gene therapy
• Upadacitinib monohydrate (Rinvoq) - restriction change
• Tyrosine kinase inhibitors (multiple) - restriction change (non-small-cell lung cancer)
• Tyrosine kinase inhibitors (multiple) - restriction change (chronic myeloid leukaemia)
• Melatonin (Slentyo) - review of previous recommendation (removal of the need for a risk sharing agreement)

The PBAC deferred the listing of:

• Nivolumab (Opdivo) and ipilimumab (Yervoy) - multiple indications
• Pembrolizumab (Keytruda) - multiple indications

The PBAC considered a broad PBS listing for nivolumab, ipilimumab and pembrolizumab would be appropriate with a risk sharing agreement that provided confidence regarding total cost to Government and cost effectiveness of a broad listing, and that a substantial price reduction versus the current PBS prices would likely be required. 

Read PBAC outcomes